SBRA Stock Analysis: Sabra Healthcare REIT | NASDAQ
REIT - Healthcare Facilities | NASDAQ, USA | Market Cap: 4.844m USD | 12M Return: 15.4% | US78573L1061 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 47.7M
Qual. Beats: 0
Rev. Trend: 97.1%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sabra Health Care REIT, Inc. (NASDAQ: SBRA) is a self-administered, self-managed real estate investment trust that owns and invests in healthcare-related real estate across the United States and Canada. The company was incorporated on May 10, 2010, and is headquartered in Tustin, California. It trades as common stock on NASDAQ with a mid-cap market capitalization of $5,071M USD and an IPO date of April 2, 2002. Under the GICS classification, SBRA falls within the Real Estate sector and the Health Care REITs sub-industry.
As a healthcare-focused REIT, Sabra generates revenue primarily through lease income and rental payments from operators of healthcare facilities, such as skilled nursing, senior housing, and other medical properties. REITs are generally required to distribute the majority of their taxable income to shareholders as dividends, and a self-administered, self-managed structure indicates that Sabra handles its own property management and operations internally rather than outsourcing these functions to third parties.
- Skilled nursing occupancy gains drive same-store NOI growth
- EnSign Group acquisition expands managed portfolio exposure
- Rising interest rates pressure REIT dividend yield competitiveness
| Net Income: 65.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.08 > 1.0 |
| NWC/Revenue: 41.11% < 20% (prev 18.38%; Δ 22.73% < -1%) |
| CFO/TA 0.07 > 3% & CFO 371.6m > Net Income 65.4m |
| Net Debt (2.43b) to EBITDA (390.9m): 6.22 < 3 |
| Current Ratio: 43.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (252.3m) vs 12m ago 4.71% < -2% |
| Gross Margin: 61.84% > 18% (prev 67.34%; Δ -5.50% > 0.5%) |
| Asset Turnover: 15.86% > 50% (prev 13.76%; Δ 2.10% > 0%) |
| Interest Coverage Ratio: 1.54 > 6 (EBIT TTM 181.5m / Interest Expense TTM 118.2m) |
| A: 0.06 (Total Current Assets 361.7m - Total Current Liabilities 8.28m) / Total Assets 5.51b |
| B: -0.39 (Retained Earnings -2.15b / Total Assets 5.51b) |
| C: 0.03 (EBIT TTM 181.5m / Avg Total Assets 5.42b) |
| D: 1.00 (Book Value of Equity 2.75b / Total Liabilities 2.76b) |
| Altman-Z'' = 0.42 = B |
As of October 17, 2026, the stock is trading at USD 19.34 with a total of 1,716,648 shares traded. Over the past week, the price has changed by +2.00%, over one month by -3.73%, over three months by -2.62% and over the past year by +15.42%.
Current recommended Stop Loss: 18.70 (which is 3.3% or 1.6 ATR below the current price).
Sabra Healthcare REIT has received a consensus analysts rating of 3.69. Therefore, it is recommended to hold SBRA.
- StrongBuy: 5
- Buy: 1
- Hold: 10
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.8 | 17.8% |
P/E Trailing = 75.84
P/E Forward = 32.1543
P/S = 5.6075
P/B = 1.8282
P/EG = 5.2841
Revenue TTM = 859.6m USD
EBIT TTM = 181.5m USD
EBITDA TTM = 390.9m USD
Long Term Debt = 2.31b USD (from longTermDebt, last quarter)
Short Term Debt = 1.08m USD (from shortTermDebt, last quarter)
Debt = 2.66b USD (from shortLongTermDebtTotal, last quarter) + Leases 19.1m
Net Debt = 2.43b USD (calculated: Debt 2.66b - CCE 231.6m)
Enterprise Value = 7.28b USD (4.84b + Debt 2.66b - CCE 231.6m)
Interest Coverage Ratio = 1.54 (Ebit TTM 181.5m / Interest Expense TTM 118.2m)
EV/FCF = 27.70x (Enterprise Value 7.28b / FCF TTM 262.7m)
FCF Yield = 3.61% (FCF TTM 262.7m / Enterprise Value 7.28b)
FCF Margin = 30.56% (FCF TTM 262.7m / Revenue TTM 859.6m)
Net Margin = 7.61% (Net Income TTM 65.4m / Revenue TTM 859.6m)
Gross Margin = 61.84% ((Revenue TTM 859.6m - Cost of Revenue TTM 328.0m) / Revenue TTM)
Gross Margin QoQ = 60.88% (prev 61.38%)
Tobins Q-Ratio = 1.32 (Enterprise Value 7.28b / Total Assets 5.51b)
Interest Expense / Debt = 4.43% (Interest Expense 118.2m / Debt 2.66b)
Taxrate = 3.26% (2.13m / 65.4m)
NOPAT = 175.6m (EBIT 181.5m * (1 - 3.26%))
Current Ratio = 4.46 (Total Current Assets 361.7m / Total Current Liabilities 81.1m)
Debt / Equity = 0.97 (Debt 2.66b / totalStockholderEquity, last quarter 2.75b)
Debt / EBITDA = 6.22 (Net Debt 2.43b / EBITDA 390.9m)
Debt / FCF = 9.26 (Net Debt 2.43b / FCF TTM 262.7m)
Total Stockholder Equity = 2.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.21% (Net Income 65.4m / Total Assets 5.51b)
RoE = 2.34% (Net Income TTM 65.4m / Total Stockholder Equity 2.80b)
RoCE = 3.56% (EBIT 181.5m / Capital Employed (Equity 2.80b + L.T.Debt 2.31b))
RoIC = 3.21% (NOPAT 175.6m / Invested Capital 5.46b)
WACC = 4.68% (E(4.84b)/V(7.51b) * Re(4.90%) + D(2.66b)/V(7.51b) * Rd(4.43%) * (1-Tc(0.03)))
Discount Rate = 4.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.71 | Cagr: 3.52%
[DCF] Terminal Value 73.10% ; FCFF base≈303.6m ; Y1≈266.3m ; Y5≈215.1m
[DCF] Fair Price = 3.99 (EV 3.45b - Net Debt 2.43b = Equity 1.02b / Shares 255.5m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.52 | # QB: 0
Revenue Correlation: 97.14 | Revenue CAGR: 12.88% | SUE: 2.26 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.17 | Chg30d=-1.02% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.45 | Chg30d=-8.01% | Revisions=-50% | GrowthEPS=-30.4% | GrowthRev=+19.8%
EPS next Year (2027-12-31): EPS=0.81 | Chg30d=+6.58% | Revisions=+25% | GrowthEPS=+15.9% | GrowthRev=+9.3%
[Analyst] Revisions Ratio: -38% (up=1, down=4)